March 5, 2013 By Robert-Barron Graham -- Barron's Medical Journal Reporting From Methodist Hospital Houston, Texas USA
President Clinton And Tony Blair Investment In Genomic Science Has Paid Off For The United States and Great Brittan
Houston ( AP ) On June 26, 2000 ---- PRESIDENT CLINTON ANNOUNCES THE COMPLETION OF THE FIRST SURVEY OF THE ENTIRE HUMAN GENOME with Public and Private Efforts to join forces. This 
was A historic White House event, with British Prime Minister Tony Blair, President Clinton announced that the international Human Genome Project and Celera Genomics Corporation have both completed an initial sequencing of the human genome -- the genetic blueprint for human beings.
President Obama Said In The State of the Union --” Tonight, thanks to .... Every dollar we invested to map the human genome returned $140 to our economy -- every dollar" Genomics is The Key To A Breast Cancer Cure:
Brought To You By 43RD Restaurant
Thirteen years later in Houston, Texas as a group of investors are looking to open " The Sam Houston Biotech Center". Barrons's Medical Journal decided to look at what is now going on with some of the achievement in Genomic Science.
Breast Cancer is the number one beneficary from the efforts of President Clinton and Prime Minster Blair. Scientist and Researchers now know that a 21-Gene RT-PCR Assay in Lymph-Node"Negative, Estrogen-Receptor"Positive in Early-Stage Breast Cancer Patients, at 40 years of age will almost be guaranteed that a breast cancer patient will live to the age of sixty cancer free.Genomics is the main reasons for the reduction of unnecessary chemotherapy.Let's take a look at the Numbers
Brought To You By Orange Shoe Personal Fitness Video:
Patients receiving the assay were predicted to gain 0.127 QALY and save $4359 annually from avoiding chemotherapy, adverse events, supportive care, and secondary primary tumors. For a 2-million member plan, net gains were 4.44 QALYs/year and savings were $13,476/year. Cost savings were greater for the Medicare population. Although overall results were sensitive only to reduced impact of testing and chemotherapy costs, they were still highly cost-effective (incremental cost-effectiveness ratio <$20,000/QALY).
Use of a 21-gene assay in patients with early-stage N (1-3)/ER HER2-negative breast cancer may improve health outcomes and add no incremental cost, thereby providing valuable insight for health plans, the Centers for Medicare and Medicaid Services, and clinicians regarding coverage policies and treatment decisions.
In summary, the recurrence score for predicting risk of distant recurrence from LN-, ER+ ESBC was shown prospectively to more accurately forecast outcomes than existing guidelines. The recurrence score, derived from a 21-gene RT-PCR assay—one of the first commercially available genomic assays—shows potential to align adjuvant chemotherapy decisions more closely with risk, thereby improving quality-adjusted survival and providing more efficient use of resources for managing breast cancer. The results of this analysis should help in developing guidelines to assure optimal and efficient use of the assay. Genomics is also helpful for the eyes
An international group of researchers has discovered seven new regions of the human genome — called loci — that are associated with increased risk of age-related macular degeneration (AMD), a leading cause of blindness. The AMD Gene Consortium, a network of international investigators representing 18 research groups, also confirmed 12 loci identified in previous studies. The findings are reported online today in the journal Nature Genetics. Supported by the National Eye Institute (NEI), a part of the National Institutes of Health, the study represents the most comprehensive genome-wide analysis of genetic variations associated with AMD. “This compelling analysis by the AMD Gene Consortium demonstrates the enormous value of effective collaboration,” said NEI Director Paul A. Sieving, M.D., Ph.D. “Combining data from multiple studies, this international effort provides insight into the molecular basis of AMD, which will help researchers search for causes of the disease and will inform future development of new diagnostic and treatment strategies.” AMD affects the macula, a region of the retina responsible for central vision. The retina is the layer of light-sensitive tissue in the back of the eye that houses rod and cone photoreceptor cells. Compared with the rest of the retina, the macula is especially dense with cone photoreceptors and is what humans rely on for tasks that require sharp vision, such as reading, driving, and recognizing faces. As AMD progresses, such tasks become more difficult and eventually impossible. Some kinds of AMD are treatable if detected early, but no cure exists. An estimated 2 million Americans have AMD.
Scientists have shown that age, diet, and smoking influence a person’s risk of developing AMD. Genetics also plays a strong role. AMD often runs in families and is more common among certain ethnicities, such as people of Asian or European descent. We are now in "The Genomic Reveloution " says Gennxeix Biotech Inc and Sam Houston Biotech Center is a World Wide effort to attract Scientist and Researcher from all over The Globe to Work and collaborate in Houston.
No comments:
Post a Comment